A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
Recruiting · NCT07326137 · Observational (researchers observe without assigning treatment) · Lead sponsor: Tongji Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs. Patients in this study will receive the Celiac Plexus Block procedure, which is intended to reduce pain, and will then begin their standard cancer medication regimen. Researchers will observe and compare how well this combined approach works to control pain and the cancer itself, and will monitor for any side effects. Participation in this study involves being followed by the research team for up to 2 years to track health outcomes. The goal is to see if starting cancer treatment together with this specialized pain management technique is more helpful for patients compared to what is already known about the standard treatments alone.
Who can take part
Inclusion criteria
- Histologically confirmed advanced biliopancreatic malignancy (including biliary tract cancer or pancreatic cancer).
- Cancer-related pain: Baseline Numeric Rating Scale (NRS) pain score ≥ 4 points for over 1 week, with plans to receive celiac plexus neurolysis (CPN).
- Scheduled to receive a first-line systemic treatment regimen (e.g., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy/targeted therapy).
- ECOG Performance Status of 0-2 and an estimated life expectancy of ≥ 3 months.
Exclusion criteria
- Previous history of celiac plexus neurolysis or ablation.
- Coagulation disorders (INR \> 1.5, platelet count \< 50 × 10⁹/L).
- Severe cardiac, hepatic, or renal insufficiency (Child-Pugh Class C, estimated glomerular filtration rate (eGFR) \< 30 mL/min, NYHA Class III-IV heart failure).
- Contraindications to celiac plexus block (e.g., local infection, anatomical variation).
- Any other condition that, in the investigator's judgment, would preclude safe participation in the study.
Where it is running
1 location listed.
- Tongji Hospital - Wuhan, Hubei, China